期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 59, 期 24, 页码 2159-2164出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.02.026
关键词
clopidogrel; coronary disease; platelet aggregation; prasugrel; stent
资金
- Lilly Research Laboratories
- Eli Lilly Co.
- Daiichi Sankyo
- AstraZeneca
- sanofi-aventis
- Abbott Vascular
- Boston Scientific
- Medtronic
- Merck
- Medicines Company
- Bristol-Myers Squibb
- Bayer-Schering
- Cordis
- Daichii Sankyo
- Portola
- Novartis
- Medicure
- Accumetrics
- Arena Pharmaceuticals
- Evolva
- GlaxoSmithKline
- Otsuka
- Schering-Plough
- Eisai
- Cordis Johnson Johnson
Objectives This study sought to investigate the efficacy, safety, and antiplatelet effect of prasugrel as compared with clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after elective percutaneous coronary intervention (PCI). Background The extent to which prasugrel can correct HTPR and improve clinical outcomes in patients undergoing elective PCI is unknown. Methods Stable coronary artery disease (CAD) patients with HTPR (>208 P2Y(12) reaction units [PRU] by the VerifyNow test) after elective PCI with at least 1 drug-eluting stent (DES) were randomly assigned to either prasugrel 10 mg daily or clopidogrel 75 mg daily. Platelet reactivity of the patients on the study drug was reassessed at 3 and 6 months. The study was stopped prematurely for futility because of a lower than expected incidence of the primary endpoint. Results In 212 patients assigned to prasugrel, PRU decreased from 245 (225 to 273) (median [interquartile range]) at baseline to 80 (42 to 124) at 3 months, whereas in 211 patients assigned to clopidogrel, PRU decreased from 249 (225 to 277) to 241 (194 to 275) (p < 0.001 vs. prasugrel). The primary efficacy endpoint of cardiac death or myocardial infarction at 6 months occurred in no patient on prasugrel versus 1 on clopidogrel. The primary safety endpoint of non-coronary artery bypass graft Thrombolysis In Myocardial Infarction major bleeding at 6 months occurred in 3 patients (1.4%) on prasugrel versus 1 (0.5%) on clopidogrel. Conclusions Switching from clopidogrel to prasugrel in patients with HTPR afforded effective platelet inhibition. However, given the low rate of adverse ischemic events after PCI with contemporary DES in stable CAD, the clinical utility of this strategy could not be demonstrated. (Testing platelet Reactivity In patients underGoing elective stent placement on clopidogrel to Guide alternative thErapy with pRasugrel [TRIGGER-PCI]; NCT00910299) (J Am Coll Cardiol 2012;59:xxx) (C) 2012 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据